MXRA8 and neoplasm: This suggests that ASP-3 can be used as an antitumor drug, and its molecular mechanism may be achieved by activating the ATG9B/VEGF signaling pathway to inhibit tumor angiogenesis-mediated cell invasion, which needs further study.